Changeflow GovPing Healthcare & Life Sciences Pritelivir Crystalline Form Patent Application
Routine Notice Added Final

Pritelivir Crystalline Form Patent Application

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO has published a patent application (US20260085068A1) filed by Assembly Biosciences, Inc. on August 28, 2023. The application describes a novel crystalline form of the antiviral drug pritelivir, intended for the treatment of herpes virus.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a publication of a patent application filed by Assembly Biosciences, Inc. for a novel crystalline form of pritelivir. The application details pharmaceutical compositions, methods for production, and the use of this crystalline form in treating herpes virus infections. The filing date was August 28, 2023, and the publication number is US20260085068A1.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on drug manufacturers. However, it signifies potential future intellectual property protection and market exclusivity for Assembly Biosciences, Inc. regarding this specific crystalline form of pritelivir. Companies involved in antiviral drug development or herpes treatment should monitor the progress of this patent application and any granted patents.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

A NOVEL CRYSTALLINE FORM OF PRITELIVIR

Application US20260085068A1 Kind: A1 Mar 26, 2026

Assignee

Assembly Biosciences, Inc.

Inventors

Zhixin ZONG, Nicole WHITE, Yi WU

Abstract

The invention relates to a novel crystalline form of pritelivir, as well as to pharmaceutical compositions comprising the same, and to methods for its production and use of the crystalline form in a medicament and for the treatment of herpes virus.

CPC Classifications

C07D 417/12 A61K 31/4439

Filing Date

2023-08-28

Application No.

19106358

View original document →

Named provisions

Abstract Assignee Inventors

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
August 28th, 2023
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260085068A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Patent Filing
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property Drug Development

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!